First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

Filip Janku*, Tae Min Kim, Gopakumar Iyer, Anna Spreafico, Elena Elez, Maja de Jonge, Noboru Yamamoto, Anthonie J. van der Wekken, Paolo Antonio Ascierto, Michela Maur, Frederik Marmé, Jean Jacques Kiladjian, Sumit Basu, Fabienne Baffert, Amparo Buigues, Chi Chen, Vesselina Cooke, Elisa Giorgetti, Jaeyeon Kim, Fiona McCarthyMichele Moschetta, Reinhard Dummer*

*Corresponding author voor dit werk

    Onderzoeksoutput: Article › Academic › peer review

    7 Citaten (Scopus)
    51 Downloads (Pure)

    Vingerafdruk

    Duik in de onderzoeksthema's van 'First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations'. Samen vormen ze een unieke vingerafdruk.

    Keyphrases

    Pharmacology, Toxicology and Pharmaceutical Science